Hematology & Oncology
Division of Hematology and Oncology
 |
Frederic Kaye, MD Professor Division of Hematology / Oncology University of Florida 1600 SW Archer Road/Box 100277 Gainesville, FL 32610-0277 E-mail: fkaye@ufl.edu (352) 273-7832/FAX (352) 273-5006 |
Dr. Kaye is a clinical and basic science investigator with a focus on thoracic malignancies. He is Board certified in Medical Oncology, Hematology,and Internal Medicine. He is an elected member of the American Society for Clinical Investigation, the Alpha Omega Alpha medical honor society, and serves as Associate Editor of the Journal of the National Cancer Institute.
Training:
| Degree Program |
Institution | Field/Specialty |
| BA with Honors | Johns Hopkins University, Baltimore | Sciences |
| MD with Honors | University of Maryland, Baltimore | Medicine |
| Residency | Mount Sinai Medical School, NYC | Internal Medicine |
| Fellowship | Mount Sinai Medical School, NYC | Hematology |
| Fellowship | National Cancer Institute, Bethesda | Oncology |
Academic Interests:
Molecular basis for human cancer and the clinical management of patients with thoracic malignancies.
Clinical Interests:
Lung Cancer, mesothelioma, salivary gland tumors
Representative Publications:
- Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 21, 6908 – 6914, 2002.
- Tonon G, Modi S, Wu L, Kubo A, Coxon A, Komiya, T, O’Neil K, Stover K, El-Naggar A, Griffin J, Kirsch I, Kaye FJ. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nature Genetics 33:208-213, 2003.
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabrieb S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naok K, Sasaki H, Fuji Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004.
- Coxon A, Rozenblum E, Park Y, Joshi N, Tsurutani J, Dennis P, Kirsch I, Kaye FJ. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cAMP/CREB regulated genes. Cancer Res 65:7137-7144, 2005.
- Thomas R et al. High-throughput oncogene mutation profiling in human cancer specimens by mass-spectrometric genotyping. Nature Genetics, 39:347-51 2007.
- Kaye FJ. Mutation associated fusion cancer genes in solid tumors. Mol Cancer Therap 8:1399-1408 2009.